NASDAQ:VNDA

Vanda Pharmaceuticals (VNDA) Stock Price, News & Analysis

Vanda Pharmaceuticals logo
$3.67 -0.08 (-2.13%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$3.66 0.00 (-0.14%)
As of 11/19/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Vanda Pharmaceuticals Stock (NASDAQ:VNDA)

Advanced

Key Stats

Today's Range
$3.65
▼
$3.85
50-Day Range
$3.59
▼
$5.21
52-Week Range
$3.57
▼
$9.94
Volume
638,770 shs
Average Volume
1.31 million shs
Market Capitalization
$221.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.50
Consensus Rating
Moderate Buy

Company Overview

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders and other conditions. Headquartered in Washington, D.C., the company was founded in 2003.

Its commercial products include Fanapt (iloperidone), approved in the United States for schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder, and Hetlioz (tasimelteon), used to treat non-24-hour sleep-wake disorder and nighttime sleep disturbances associated with Smith-Magenis syndrome.

Vanda also develops investigational medicines, including tradipitant, which it has studied for conditions such as motion sickness and gastroparesis. Its commercial activities are centered on the U.S. market.

AI Generated. May Contain Errors.

Vanda Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

VNDA MarketRank™: 
4.089720655015 of 5 stars

Vanda Pharmaceuticals scored higher than 82% of companies evaluated by MarketBeat, and ranked 73rd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vanda Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Vanda Pharmaceuticals has a consensus price target of $13.50, representing about 267.8% upside from its current price of $3.67.

  • Amount of Analyst Coverage

    Vanda Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

  • Read more about Vanda Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Vanda Pharmaceuticals are expected to grow in the coming year, from ($2.53) to ($0.94) per share.

  • Price to Book Value per Share Ratio

    Vanda Pharmaceuticals has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    14.12% of the float of Vanda Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Vanda Pharmaceuticals has a short interest ratio ("days to cover") of 5.93.
  • Change versus previous month

    Short interest in Vanda Pharmaceuticals has recently decreased by 8.26%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Vanda Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Vanda Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Vanda Pharmaceuticals has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Vanda Pharmaceuticals this week, compared to 5 articles on an average week.
  • Search Interest

    5 people have searched for VNDA on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $38,069.00 in company stock, which represents 0.0172% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Vanda Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $38,069.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    10.70% of the stock of Vanda Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    88.14% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Vanda Pharmaceuticals' insider trading history.
Receive VNDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VNDA Stock News Headlines

Vanda Pharmaceuticals Earnings Call Signals Growth Amid Risks
Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
Vanda (VNDA) Q3 2026 Earnings Call Transcript
See More Headlines

VNDA Stock Analysis - Frequently Asked Questions

Vanda Pharmaceuticals' stock was trading at $8.82 at the beginning of 2026. Since then, VNDA stock has decreased by 58.4% and is now trading at $3.67.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its earnings results on Wednesday, October, 28th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.31. The biopharmaceutical company had revenue of $69.82 million for the quarter, compared to the consensus estimate of $69.20 million. Vanda Pharmaceuticals had a negative trailing twelve-month return on equity of 62.70% and a negative net margin of 119.87%.
Read the conference call transcript
.

Vanda Pharmaceuticals' top institutional investors include State Street Corp (4.98%), AIGH Capital Management LLC (3.72%), Marshall Wace LLP (3.44%) and Goldman Sachs Group Inc. (1.76%). Insiders that own company stock include Mihael Hristos Polymeropoulos, Gunther Birznieks, Kevin Patrick Moran, Timothy Williams, Joakim Wijkstrom, Charles Cliff Duncan and Stephen Ray Mitchell.
View institutional ownership trends
.

Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vanda Pharmaceuticals investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Intel (INTC), Bristol Myers Squibb (BMY), Chevron (CVX) and Palantir Technologies (PLTR).

Company Calendar

Last Earnings
10/28/2026
Today
11/19/2026
Jefferies Global Healthcare Conference
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:VNDA
CIK
1347178
Employees
533
Year Founded
2002

Price Target and Rating

High Price Target
$20.00
Low Price Target
$7.50
Potential Upside/Downside
+267.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.62)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$220.47 million
Net Margins
-119.87%
Pretax Margin
-74.67%
Return on Equity
-62.70%
Return on Assets
-37.53%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
1.54
Quick Ratio
1.53

Sales & Book Value

Annual Sales
$216.10 million
Price / Sales
1.03
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.31 per share
Price / Book
1.11

Miscellaneous

Outstanding Shares
60,470,000
Free Float
54,000,000
Market Cap
$221.92 million
Optionable
Optionable
Beta
0.74

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:VNDA) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners